← Product Code [KHE](/submissions/HE/subpart-g%E2%80%94manual-hematology-devices/KHE) · K073431

# FORSURE IFOB DUEL SAMPLE FECAL OCCULT BLOOD TEST DEVICE (FOR PROFESSIONAL AND HOME USE); (FOR PROFESSIONAL); (FOR HOME T (K073431)

_Tianjin New Bay Bioresearch Co., Ltd. · KHE · Jan 14, 2008 · Hematology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/HE/subpart-g%E2%80%94manual-hematology-devices/KHE/K073431

## Device Facts

- **Applicant:** Tianjin New Bay Bioresearch Co., Ltd.
- **Product Code:** [KHE](/submissions/HE/subpart-g%E2%80%94manual-hematology-devices/KHE.md)
- **Decision Date:** Jan 14, 2008
- **Decision:** SESE
- **Submission Type:** Special
- **Regulation:** 21 CFR 864.6550
- **Device Class:** Class 2
- **Review Panel:** Hematology

## Indications for Use

Qualitative detection of human hemoglobin from blood in fecal samples

## Device Story

Sure™ Dual Sample Fecal Occult Blood Test Device; immunochemical test for human hemoglobin in feces; modification involves housing two sample assay devices in one plastic unit instead of one; used for fecal occult blood detection; provides qualitative results; aids clinical decision-making regarding gastrointestinal bleeding; operated by laboratory personnel or healthcare providers.

## Clinical Evidence

Bench testing only; design control activities and risk analysis performed to verify modification impact; results met predetermined acceptance criteria.

## Technological Characteristics

Immunochemical test; plastic housing containing two sample assays; utilizes antibody clones 5002.

## Regulatory Identification

An occult blood test is a device used to detect occult blood in urine or feces. (Occult blood is blood present in such small quantities that it can be detected only by chemical tests of suspected material, or by microscopic or spectroscopic examination.)

## Special Controls

*Classification.* Class II (special controls). A control intended for use with an occult blood test is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.

## Predicate Devices

- Sure™ Fecal Occult Blood Test Device (K_073431)

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

SPECIAL 510(k): Device Modification

ODE Review Memorandum (Decision Making Document is Attached)

To: THE FILE
RE: DOCUMENT NUMBER K_073431 For Sure™ Dual
Sample Fecal Occult Blood Test Device

This 510(k) submission contains information/data on modifications made to the SUBMITTER'S own Class II, Class III or Class I devices requiring 510(k). The following items are present and acceptable (delete/add items as necessary):

1. The name and 510(k) number of the SUBMITTER'S previously cleared device. (For a preamendments device, a statement to this effect has been provided.)
2. Submitter's statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use).
3. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed.

This change was for combining two sample assay devices in one plastic housing instead of one sample assay device per plastic housing and accompanying labeling changes.

4. Comparison Information (similarities and differences) to applicant's legally marketed predicate device including, labeling, intended use, testing method, specimen type, and antibody clone.

|  Similarities  |   |   |
| --- | --- | --- |
|  Item | Device | Predicate  |
|  Intended use | Same | Qualitative detection of human hemoglobin from blood in fecal samples  |
|  Technology | Same | Immunochemical test  |
|  Specimen | Same | Feces  |
|  Antibody clone | Same | 5002 and 5002  |
|  Differences  |   |   |
|  Item | Device | Predicate  |
|  Number of assays in test device | 2 | 1  |

5. A Design Control Activities Summary (pp. 26-35) which includes:

a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis
b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied
c) A declaration of conformity with design controls. The declaration of conformity should include:

i) A statement signed by the individual responsible, that, as required by the risk analysis, all verification and validation activities were performed by the designated individual(s) and the results demonstrated that the predetermined acceptance criteria were met, and
ii) A statement signed by the individual responsible, that the manufacturing facility is in conformance with design control procedure requirements as specified in 21 CFR 820.30 and the records are available for review.

6. A Truthful and Accurate Statement, a 510(k) Summary or Statement and the Indications for Use Enclosure (and Class III Summary for Class III devices).

The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices

{1}

2

demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.

|  (Reviewer's Signature) | (Date)  |
| --- | --- |
|  Comments |   |

revised:8/1/03

"

---

**Source:** [https://fda.innolitics.com/submissions/HE/subpart-g%E2%80%94manual-hematology-devices/KHE/K073431](https://fda.innolitics.com/submissions/HE/subpart-g%E2%80%94manual-hematology-devices/KHE/K073431)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com